Scarica l'app Stockscreener
68.92
2.87%
-2.04
Precedente Chiudi:
$70.96
Aprire:
$70.57
Volume 24 ore:
1.54M
Relative Volume:
1.13
Capitalizzazione di mercato:
$6.66B
Reddito:
$7.50M
Utile/perdita netta:
$-383.17M
Rapporto P/E:
-14.65
EPS:
-4.7048
Flusso di cassa netto:
$-307.84M
1 W Prestazione:
+13.06%
1M Prestazione:
+34.24%
6M Prestazione:
+63.51%
1 anno Prestazione:
+108.98%
Intervallo 1D:
$67.21
$71.03
Intervallo di 1 settimana:
$59.62
$72.66
Portata 52W:
$30.00
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
68.92 | 6.66B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Understanding the Setup: (XENE) and Scalable Risk - Stock Traders Daily
Xenon Pharmaceuticals outlines epilepsy focus as pipeline advances - ad-hoc-news.de
Xenon Pharmaceuticals stock hits all-time high at 63.96 USD - Investing.com
Xenon Pharmaceuticals stock hits all-time high at 63.96 USD By Investing.com - Investing.com Canada
XENEXenon Pharmaceuticals Inc Latest SEC Filings - Finviz
Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18 - marketscreener.com
Xenon Pharmaceuticals faces earnings test as launch nears By Investing.com - Investing.com Nigeria
Price to book forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE - TradingView
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate - Moomoo
Xenon Pharmaceuticals stock gains 22% in six months: Here's why - MSN
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon awards new hires 20,200 options and 11,850 RSUs - Stock Titan
Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE - TradingView
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out - Sahm
The Technical Signals Behind (XENE) That Institutions Follow - Stock Traders Daily
Xenon Pharmaceuticals Inc. Actuals & Estimates (FWB:XP0) - TradingView
Xenon Pharmaceuticals Inc (XENE) Institutional Confidence - TradingKey
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why - sharewise.com
Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary - Quartr
Xenon Pharmaceuticals Inc. (XENE) Surges Over 3.8% as Stock Tests Key Resistance LevelsOption Breadth - dars.gov.et
Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenon Pharmaceuticals StockLong-term strategy and epilepsy pipeline in focus - Ad-hoc-news.de
Precision Trading with Xenon Pharmaceuticals Inc. (XENE) Risk Zones - Stock Traders Daily
Xenon Pharmaceuticals Inc (XENE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenon Pharmaceuticals Inc (XENE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xenon Pharmaceuticals Inc (XENE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xenon Pharmaceuticals Inc (XENE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenon Pharmaceuticals Inc (XENE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenon Pharmaceuticals (XENE) 2026 Bloom Burton & Co. Healthcare Investor Conference summary - Quartr
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan - Stock Titan
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) director receives new RSUs, options and RSU vesting - Stock Titan
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises vested RSUs - Stock Titan
Xenon Pharmaceuticals (XENE) director receives RSUs, options and nets vested shares - Stock Titan
Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes - Stock Titan
Xenon (XENE) director receives RSUs, options and adds common shares - Stock Titan
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Xenon Pharmaceuticals Inc. Rings the Opening Bell - Nasdaq
Wells Fargo Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Xenon Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
XENE Q1 2026 Earnings: EPS Beat Amid Continued Clinical Development FocusOne-Time Gain Impact - newsline.com
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):